Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First Cell-Derived Flu Vaccine Reaches Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

Protein Sciences' seasonal influenza vaccine FluBlok has typical immunity data but some manufacturing issues.
Advertisement

Related Content

Synthetic Cell Technology Could Benefit Vaccine Production, Venter Says
Synthetic Cell Technology Could Benefit Vaccine Production, Venter Says
Protein Sciences "Dumbfounded" After Committee Votes Down FluBlok
Protein Sciences "Dumbfounded" After Committee Votes Down FluBlok
Adjuvant Vaccines Could Have Helped To Prevent H1N1 Shortfall, Industry Tells Congress
Adjuvant Vaccines Could Have Helped To Prevent H1N1 Shortfall, Industry Tells Congress

Topics

Advertisement
UsernamePublicRestriction

Register

PS068764

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel